Advertisement

Topics

Ertugliflozin

17:20 EST 22nd November 2017 | BioPortfolio

Ertugliflozin a sodium glucose cotransporter-2 (SGLT2) inhibitor, under development by Pfizer and Merck & Co. for the treatment of type 2 diabetes (T2D).  By blocking SGLT2 in the proximal tubules of the kidney, ertugliflozin removes excess glucose in the blood by preventing the reabsorption of filtered glucose.

Quick Search
Advertisement
 

review and buy Ertugliflozin market research data and corporate reports here